Amgen (AMGN) Change in Accured Expenses (2009 - 2026)

Amgen (AMGN) has reported Change in Accured Expenses for 18 consecutive years, with -$75.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 3.85% year-over-year to -$75.0 million; the TTM figure through Mar 2026 stood at -$153.0 million (down 318.57% YoY), while the FY2025 annual figure was -$156.0 million, down 269.57% from the prior year.
• Change in Accured Expenses came in at -$75.0 million for Q1 2026 at Amgen, down from $94.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2023, with the low at -$501.0 million in Q3 2023.
• Average Change in Accured Expenses over 5 years is $53.6 million, with a median of -$75.0 million recorded in 2026.
• The largest YoY upside for Change in Accured Expenses was 401.37% in 2023 against a maximum downside of 219.57% in 2023.
• Year by year, Change in Accured Expenses stood at -$366.0 million in 2022, then jumped by 401.37% to $1.1 billion in 2023, then sank by 34.0% to $728.0 million in 2024, then slumped by 87.09% to $94.0 million in 2025, then plunged by 179.79% to -$75.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$75.0 million, $94.0 million, and -$180.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.